Microsoft's 2029 quantum supercomputer ambitions may have hit a roadblock, as critics claim the company's 2025 quantum ...
Syntax Bio expands Series A to $14.4M to boost CRISPR Cellgorithm platform and type 1 diabetes beta-cell therapy amid tough biotech funding—read more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results